Chemotherapy Induced Febrile Neutropenia Clinical Trials

DelveInsight reports that more than four key companies are actively developing over four therapeutic candidates for Chemotherapy-Induced Febrile Neutropenia (CIFN).

Chemotherapy Induced Febrile Neutropenia Overview:

Chemotherapy-Induced Febrile Neutropenia (CIN) is a major dose-limiting complication for cancer patients receiving chemotherapy. It can result in febrile neutropenia (FN) and is associated with increased morbidity, early mortality, higher healthcare costs, and interruptions to essential cancer treatments. The risk and severity of CIN, including complications like fever, infections, and chemotherapy dose modifications, vary by cancer type. According to a large prospective registry, CIN occurred in 15% to 65% of patients across five major cancers—breast, colon, lymphoma, lung, and ovarian—while the incidence of FN ranged from 7% to 30%.

Request for a detailed insights report on Chemotherapy Induced Febrile Neutropenia pipeline insights

“Chemotherapy Induced Febrile Neutropenia Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chemotherapy Induced Febrile Neutropenia Therapeutics Market.

Key Takeaways from the Chemotherapy Induced Febrile Neutropenia Pipeline Report

• DelveInsight’s Chemotherapy-Induced Febrile Neutropenia (CIN) pipeline report highlights an active landscape with over four companies developing more than four therapeutic candidates for CIN treatment.

• Ryzneuta, approved in November 2023, is a long-acting G-CSF indicated to reduce the risk of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy.

• Rolvedon, approved in September 2022, is another long-acting G-CSF designed to decrease the incidence of infection, as manifested by febrile neutropenia, in adults undergoing myelosuppressive chemotherapy.

• Key players such as BeyondSpring Pharmaceuticals, Enzychem Lifesciences, Tianjin SinoBiotech Ltd., Evive Biotech, and others are actively evaluating new therapies to improve the CIN treatment landscape.

• Promising pipeline candidates in development include Plinabulin, EC-18, and others in various stages of clinical evaluation.

Chemotherapy Induced Febrile Neutropenia Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Chemotherapy Induced Febrile Neutropenia Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Febrile Neutropenia treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chemotherapy Induced Febrile Neutropenia market.

Download our free sample page report on Chemotherapy Induced Febrile Neutropenia pipeline insights

Chemotherapy Induced Febrile Neutropenia Emerging Drugs

• Plinabulin: BeyondSpring Pharmaceuticals

• EC-18: Enzychem Lifesciences

Chemotherapy Induced Febrile Neutropenia Companies

Approximately four leading companies are developing therapies for chemotherapy-induced febrile neutropenia, with BeyondSpring Pharmaceuticals advancing the most progressed candidates, currently at the preregistration stage.

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Chemotherapy Induced Febrile Neutropenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Chemotherapy Induced Febrile Neutropenia Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Chemotherapy Induced Febrile Neutropenia Therapies and Key Companies: Chemotherapy Induced Febrile Neutropenia Clinical Trials and advancements

Chemotherapy Induced Febrile Neutropenia Pipeline Therapeutic Assessment

• Chemotherapy Induced Febrile Neutropenia Assessment by Product Type

• Chemotherapy Induced Febrile Neutropenia By Stage

• Chemotherapy Induced Febrile Neutropenia Assessment by Route of Administration

• Chemotherapy Induced Febrile Neutropenia Assessment by Molecule Type

Download Chemotherapy Induced Febrile Neutropenia Sample report to know in detail about the Chemotherapy Induced Febrile Neutropenia treatment market @ Chemotherapy Induced Febrile Neutropenia Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Chemotherapy Induced Febrile Neutropenia Current Treatment Patterns

4. Chemotherapy Induced Febrile Neutropenia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chemotherapy Induced Febrile Neutropenia Late-Stage Products (Phase-III)

7. Chemotherapy Induced Febrile Neutropenia Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chemotherapy Induced Febrile Neutropenia Discontinued Products

13. Chemotherapy Induced Febrile Neutropenia Product Profiles

14. Chemotherapy Induced Febrile Neutropenia Key Companies

15. Chemotherapy Induced Febrile Neutropenia Key Products

16. Dormant and Discontinued Products

17. Chemotherapy Induced Febrile Neutropenia Unmet Needs

18. Chemotherapy Induced Febrile Neutropenia Future Perspectives

19. Chemotherapy Induced Febrile Neutropenia Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Chemotherapy Induced Febrile Neutropenia Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/